305 Study
305 Study. Randomised, Double Blind, Placebo Controlled Phase III Safety and Efficacy Study (8 and 12 mg OD) Conducted in Europe, Asia, North America, Australia, and South Africa. Study design: Phase III study number: E2007-G000-305 ( NCT00699582). Design
435 views • 24 slides